These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34325944)

  • 1. NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers.
    Brooker RC; Schache AG; Sacco JJ
    Br J Oral Maxillofac Surg; 2021 Oct; 59(8):959-962. PubMed ID: 34325944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
    Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
    JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
    Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
    Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
    Furness S; Glenny AM; Worthington HV; Pavitt S; Oliver R; Clarkson JE; Macluskey M; Chan KK; Conway DI;
    Cochrane Database Syst Rev; 2010 Sep; (9):CD006386. PubMed ID: 20824847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
    Furness S; Glenny AM; Worthington HV; Pavitt S; Oliver R; Clarkson JE; Macluskey M; Chan KK; Conway DI
    Cochrane Database Syst Rev; 2011 Apr; (4):CD006386. PubMed ID: 21491393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for Oral Cancer.
    Hartner L
    Dent Clin North Am; 2018 Jan; 62(1):87-97. PubMed ID: 29126496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
    BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Wang R; Liu S; Chen B; Xi M
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.
    Shen P; Qiao B; Jin N; Wang S
    Invest New Drugs; 2022 Dec; 40(6):1282-1289. PubMed ID: 35972629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors.
    Specenier P
    Curr Opin Otolaryngol Head Neck Surg; 2021 Apr; 29(2):168-177. PubMed ID: 33605624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
    Shah H; Wang Y; Cheng SC; Gunasti L; Chen YH; Lako A; Guenette J; Rodig S; Jo VY; Uppaluri R; Haddad R; Schoenfeld JD; Jacene HA
    JAMA Otolaryngol Head Neck Surg; 2022 Mar; 148(3):268-276. PubMed ID: 35050348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
    Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
    Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
    Front Immunol; 2022; 13():970823. PubMed ID: 36389668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers.
    Patil VM; Noronha V; Joshi A; Banavali SD; Muddu V; Prabhash K
    Oncology; 2016; 91 Suppl 1():35-40. PubMed ID: 27463093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
    Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
    Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.